Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|December 18, 2016
Practical Considerations in Managing Relapsed Multiple MyelomaAmit Agarwal, Eric Chow, Manisha Bhutani, et al.
Expert Review of Hematology|January 30, 2014
Current strategies for treatment of relapsed/refractory multiple myelomaJacob P Laubach, Peter M Voorhees, Hani Hassoun, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignanciesNishitha Reddy, Peter M Voorhees, Brett E Houk, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 29, 2017
Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple MyelomaPeter M Voorhees, Cristina Gasparetto, Dominic T Moore, et al.
Blood|December 4, 2008
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitorsDeborah J Kuhn, Sally A Hunsucker, Qing Chen, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|January 27, 2018
Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidicsJoyce W Kamande, Maria A M Lindell, Małgorzata A Witek, et al.
The Lancet. Haematology|February 7, 2020
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trialsFrits van Rhee, Corey Casper, Peter M Voorhees, et al.
Archives of Pathology & Laboratory Medicine|January 23, 2004
Follicular lymphoma with a burkitt translocation--predictor of an aggressive clinical course: a case report and review of the literaturePeter M Voorhees, Kathryn A Carder, Scott V Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphomaRichard J Jones, Qing Chen, Peter M Voorhees, et al.
British Journal of Haematology|April 7, 2009
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell deathPeter M Voorhees, Qing Chen, George W Small, et al.
Pageof 10